- Home
- KALV vs SNCY Comparison
KALV vs SNCY Comparison
Compare KALV & SNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- SNCY
- Stock Information
- Founded
- KALV N/A
- SNCY 1982
- Country
- KALV United States
- SNCY United States
- Employees
- KALV N/A
- SNCY N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- SNCY Air Freight/Delivery Services
- Sector
- KALV Health Care
- SNCY Consumer Discretionary
- Exchange
- KALV Nasdaq
- SNCY Nasdaq
- Market Cap
- KALV 637.9M
- SNCY 549.7M
- IPO Year
- KALV N/A
- SNCY 2021
- Fundamental
- Price
- KALV $15.82
- SNCY $13.17
- Analyst Decision
- KALV Strong Buy
- SNCY Buy
- Analyst Count
- KALV 9
- SNCY 7
- Target Price
- KALV $26.29
- SNCY $17.00
- AVG Volume (30 Days)
- KALV 734.1K
- SNCY 803.3K
- Earning Date
- KALV 09-09-2025
- SNCY 10-29-2025
- Dividend Yield
- KALV N/A
- SNCY N/A
- EPS Growth
- KALV N/A
- SNCY 20.75
- EPS
- KALV N/A
- SNCY 1.07
- Revenue
- KALV N/A
- SNCY $1,100,145,000.00
- Revenue This Year
- KALV N/A
- SNCY $6.16
- Revenue Next Year
- KALV $221.95
- SNCY $10.33
- P/E Ratio
- KALV N/A
- SNCY $12.31
- Revenue Growth
- KALV N/A
- SNCY 3.76
- 52 Week Low
- KALV $7.30
- SNCY $8.10
- 52 Week High
- KALV $16.32
- SNCY $18.59
- Technical
- Relative Strength Index (RSI)
- KALV 71.16
- SNCY 58.70
- Support Level
- KALV $13.72
- SNCY $12.88
- Resistance Level
- KALV $13.96
- SNCY $13.88
- Average True Range (ATR)
- KALV 0.69
- SNCY 0.50
- MACD
- KALV 0.31
- SNCY 0.09
- Stochastic Oscillator
- KALV 99.15
- SNCY 70.17
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.